A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

3期进行中（已停止招募） NCT01946204

适应症	Prostatic Neoplasms
分期	3期
申办方	Aragon Pharmaceuticals, Inc.
状态	进行中（已停止招募）
受试者人数	1,207 人
干预（药物）	Apalutamide
开始日期	2013年10月14日
完成日期	2017年5月19日
结果公布日	2018年6月19日

摘要

The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.

Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)

Up to approximately 43 Months · Months

Placebo	16.20 Months
Apalutamide	40.51 Months
Placebo	15.70 Months
Apalutamide	40.51 Months

p-value	<0.0001
Hazard Ratio (HR)	0.280 (95% CI 0.227–0.346)

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery — Wake Forest University Health Sciences
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced P — National Cancer Institute (NCI)
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castr — National Cancer Institute (NCI)
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abirate — Janssen Research & Development, LLC
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Ola — National Cancer Institute (NCI)
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Pr — Janssen Research & Development, LLC

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский